Project Grant R43DA046325

This $385,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to advance integrated treatment for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) in real-world settings. The key objectives are to: Assess the effectiveness of integrated treatment approaches, including first-line medications and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for patients with co-occurring OUD...

This federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,415,940 to the University of Massachusetts Medical School (UMass Medical) to conduct a prospective, observational study on using digital biomarkers from wearable sensors to understand craving patterns during medications for opioid use disorder (MOUD) treatment. The key goals are to: 1) curate a high-quality dataset of craving...

This Project Grant from the National Institutes of Health National Institute on Drug Abuse will fund Neurobehavioral Research Inc. to provide network synchrony neurofeedback training and evaluation for opioid dependent individuals receiving medication assisted treatment. The $807,960 award, issued on September 30, 2021, will support 12 neurofeedback sessions over 8 weeks to train participants' brains to mimic adaptive changes in resting state brain network synchrony seen with long-term...

The National Institute on Drug Abuse (NIDA) awarded a $11,872,077 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Sparian Biosciences Inc. (doing business as Palion Therapeutics) to develop SBS-226, a novel chemical entity that acts as a mu-opioid receptor agonist and delta-opioid receptor antagonist, for the treatment of opioid use disorder (OUD). The project aims to advance SBS-226 through IND-enabling studies and a Phase 1 clinical trial. Sparian...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for a $1,837,542 project titled "Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery Enhancement." The project aims to investigate the safety, preliminary efficacy, and psycho-physiological mechanisms of combining the psychotherapy Mindfulness-Oriented Recovery Enhancement (MORE) with ketamine...

The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,264,863 Project Grant to Rutgers, The State University of New Jersey on September 30, 2024. The goal of this research project is to evaluate the efficacy and neural mechanisms of a combined therapy using the medication guanfacine and the behavioral intervention mindfulness-oriented recovery enhancement (MORE) as an adjunct to buprenorphine maintenance for individuals with...

This Project Grant award of $1,539,260 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to study the role of the kappa opioid receptor (KOR) system in opioid use disorder (OUD). The key objectives are to: Use PET imaging to compare KOR availability in early abstinent individuals with moderate-to-severe OUD (N=40) versus healthy controls (N=30). Examine the clinical and transdiagnostic relevance of KOR,...

The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $594,122 Project Grant to Boulder Care, Inc. to develop and test telehealth workflows for providing buprenorphine treatment for opioid use disorder (OUD) in vulnerable settings. The project aims to address the continued lack of access to OUD treatment, particularly in jails/prisons, emergency departments, residential treatment facilities, rural tribal areas, and during the...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $235,542 to Brigham & Women's Hospital Inc. to conduct a double-blind, randomized clinical trial evaluating the safety of using extended-release buprenorphine (XR-BUP) as a low-dose induction strategy for patients with opioid use disorder. The study aims to determine if XR-BUP can be safely administered before the emergence of opioid withdrawal...

The National Institutes of Health's National Institute on Drug Abuse awarded New York University School of Medicine a $1,446,310 Project Grant under the Drug Abuse and Addiction Research Programs to adapt an evidence-based posttraumatic stress disorder intervention for polysubstance use populations receiving treatment for opioid use disorder. Specifically, the award will support adapting an existing trauma-focused therapy, Skills Training in Affective and Interpersonal Regulation with...